Wogonin is a naturally occurring mono-flavonoid, can inhibit the activity of CDK8 and Wnt, and exhibits anti-inflammatory and anti-tumor effects.
Description :
Wogonin inhibits PMA-induced COX-2 gene expression by inhibiting c-Jun expression and AP-1 activation in A549 cells[1]. Wogonin is an inhibitor of cyclin-dependent kinase 9 (CDK9) and block phosphorylation of the carboxy-terminal domain of RNA polymerase II at Ser. Thus, it reduces RNA synthesis and subsequently rapid downregulation of the short-lived anti-apoptotic protein myeloid cell leukemia 1 (Mcl-1) resulting in apoptosis induction in cancer cells. Wogonin directly binds to CDK9, presumably to the ATP-binding pocketa and does not inhibit CDK2, CDK4 and CDK6 at doses that inhibit CDK9 activity. Wogonin preferentially inhibits CDK9 in malignant compared with normal lymphocytes. Wogonin is a also potent anti-oxidant capable to scavenge •O2− [2]. Wogonin significantly inhibits the translocation of NFATc1 from the cytoplasm to the nucleus and its transcriptional activation activity. It also significantly inhibits osteoclast differentiation and decreases the transcription of osteoclast‑associated immunoglobulin‑like receptor, tartrate‑resistant acid phosphatase and calcitonin receptor[4]. Wogonin Inhibits N-acetyltransferase Activity[5].
Wogonin (30, 60 mg/kg) reduces tumor growth of HCT116 cells in a xenograft model[1]. Wogonin (25, 50, 100 mg/kg) protects against liver injury and pathological characteristics of ALD in mice. Wogonin activates PPAR-γ expression in mice with ALD and EtOH induced RAW264.7 cells[3].